INDOLENT NON-HODGKIN LYMPHOMA
Clinical trials for INDOLENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new INDOLENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for INDOLENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy combo shows promise for untreated lymphoma patients
Disease control OngoingThis study tests a combination of two immunotherapy drugs, glofitamab and obinutuzumab, in 47 people with follicular lymphoma or marginal zone lymphoma who have not had prior treatment. The goal is to see how well the drugs control the cancer by measuring complete metabolic respo…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Reid Merryman, MD • Aim: Disease control
Last updated May 17, 2026 03:23 UTC
-
Immunotherapy-Chemo combo shows promise for tough lymphoma
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can help people with aggressive B-cell non-Hodgkin lymphoma. About 30 adults with advanced stages of the disease are taking part. The main goal is to see how long the c…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for aggressive lymphoma: targeted drug combo shows promise
Disease control OngoingThis study tests a new drug called parsaclisib added to standard chemotherapy (R-CHOP) for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. The goal is to find the best dose and see if the combination is safe and works better than standard treatment alone. Ab…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug duo shows promise against Hard-to-Treat lymphoma
Disease control OngoingThis study tests whether combining two drugs—obinutuzumab and ibrutinib—can shrink or eliminate slow-growing non-Hodgkin's lymphoma in people who haven't been treated before. About 30 adults with various stages of the disease will receive the drugs as their first therapy. The goa…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Cancer drug trial pulled before it even started
Disease control TerminatedThis was a Phase I trial testing a drug called CB-5339 in people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the best dose and check for side effects. However, the study was withdrawn before enrolling any partic…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:21 UTC
-
New combo therapy targets tough blood cancers in early trial
Disease control OngoingThis early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with Richter's transformation or certain non-Hodgkin lymphomas. The goal is to find the safest dose and see how well the drugs work together. About 27 adults will take part, and the study…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:18 UTC